Showing results (671-680 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|December 18, 2007
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3Thierry Gorlia, Martin J van den Bent, Monika E Hegi, et al.
The Lancet. Oncology|December 7, 2007
Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidenceFei Xue, Karin B Michels
The Lancet. Oncology|December 7, 2007
Part II: management of resistance to imatinib in chronic myeloid leukaemiaJane F Apperley
The Lancet. Oncology|November 20, 2016
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsGeorgina V Long, Jean-Jacques Grob, Paul Nathan, et al.
The Lancet. Oncology|November 20, 2016
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial dataJustin Guinney, Tao Wang, Teemu D Laajala, et al.
The Lancet. Oncology|October 14, 2016
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialPadmanee Sharma, Margaret K Callahan, Petri Bono, et al.
The Lancet. Oncology|November 10, 2016
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trialAlexander Drilon, Natasha Rekhtman, Maria Arcila, et al.
The Lancet. Oncology|November 10, 2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trialJoel W Neal, Suzanne E Dahlberg, Heather A Wakelee, et al.
The Lancet. Oncology|May 6, 2014
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trialIan E Krop, Sung-Bae Kim, Antonio González-Martín, et al.
The Lancet. Oncology|May 6, 2014
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialGunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, et al.
Pageof 336